Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sales Level Off for Year Ended Feb 2012 on Effects of Earthquake: Hisamitsu
April 11, 2012
- Sales of Ethical Drugs Up 8.7% in February: Crecon Report
April 10, 2012
- GSK Ties Up with Chiome for Antibody Generation Technology
April 10, 2012
- Fuso, Kaken to Jointly Market Topical Hemostatic Agent
April 10, 2012
- Ethical Drug Production in 2019 Predicted at 11 Trillion Yen: Yano Research Survey
April 10, 2012
- Anticoagulant Market to Heat Up with Lifting of Ban on Long-term Prescription of Prazaxa, Debut of New Products
April 10, 2012
- Generics Made in India to Storm Japanese Market with Overwhelming Price Advantage
April 10, 2012
- Bayer Yakuhin to Focus on 2 Prospective Blockbusters, Target 200 Billion Yen in Sales in 2013: President Guth
April 9, 2012
- US FDA Recommends Approval of Mirabegron from Astellas
April 9, 2012
- Sanofi-aventis, Alfresa Agree on Joint Development of Antiepileptic Drug
April 9, 2012
- Ohara Pharmaceutical Begins Development of Glucarpidase, Aims to File for Approval in 2014
April 9, 2012
- Eisai Establishes Aricept Director Position
April 6, 2012
- MTPC Complements Alliance with BIKEN to Establish Its Own Vaccine Development Infrastructure
April 6, 2012
- BMKK Posts 1st Increase in Sales Since 2005: President & CEO Emmanuel Blin
April 6, 2012
- Eisai Signs Agreement on Marketing Halaven in 8 Central and Eastern European Countries
April 6, 2012
- Toray Grants German Company Marketing Rights for Antipruritic Agent in Europe
April 6, 2012
- Takeda Considering Manufacturing Plant Move on Power Shortage: Keizai Doyukai Chairman Hasegawa
April 5, 2012
- Nihon Chouzai to Soon Conclude Memorandum with Wholesalers for Provisional Prices
April 5, 2012
- Pharmacists Expect Increase in Use of Amlodipine Generics: Survey
April 5, 2012
- GSK Applies for Fixed-Dose Combination Tablet for Treatment/Prevention of Malaria
April 5, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…